surmount-1 tirzepatide weight loss results Analysis of Acquisition Costs and Reduction Outcomes in the United Kingdom: Insights from the Study | Advances in Therapy Tirzepatide Before and After Results:

The process for a compounded drug does not include this testing

The medication does not stop your metabolism from slowing down

Current head-to-head evidence suggests tirzepatide may produce greater average weight loss than semaglutide

Tirzepatide is a dual GLP-1 and GIP receptor agonist licensed in the UK for type 2 diabetes management

For patients comparing the two medications, the semaglutide versus tirzepatide comparison page breaks down the clinical differences, side effect profiles, and efficacy data to help you decide which is the better fit

Only pre-filled injection pens (Mounjaro and Zepbound) manufactured by Eli Lilly are approved, as compounded or reconstituted powder forms carry risks of contamination, dosing errors, and unknown ingredient stability